| name | tooluniverse-infectious-disease |
| description | Rapid pathogen characterization and drug repurposing for outbreaks. Combines pathogen genomics (NCBI, BVBRC), host immune response (IEDB), drug-target databases (ChEMBL, DGIdb), and literature surveillance (PubMed/EuropePMC). Use for emerging-pathogen profiling, antiviral candidate identification, and outbreak intelligence reporting. |
COMPUTE, DON'T DESCRIBE
When analysis requires computation (statistics, data processing, scoring, enrichment), write and run Python code via Bash. Don't describe what you would do — execute it and report actual results. Use ToolUniverse tools to retrieve data, then Python (pandas, scipy, statsmodels, matplotlib) to analyze it.
Infectious Disease Outbreak Intelligence
Rapid response system for emerging pathogens using taxonomy analysis, target identification, structure prediction, and computational drug repurposing.
KEY PRINCIPLES:
- Speed is critical - Optimize for rapid actionable intelligence
- Target essential proteins - Focus on conserved, essential viral/bacterial proteins
- Leverage existing drugs - Prioritize FDA-approved compounds for repurposing
- Structure-guided - Use NvidiaNIM for rapid structure prediction and docking
- Evidence-graded - Grade repurposing candidates by evidence strength
- Actionable output - Prioritized drug candidates with rationale
- English-first queries - Always use English terms in tool calls; respond in user's language
REASONING STRATEGY — Start Here:
Start with pathogen identification: What type of organism? (virus, bacteria, fungus, parasite). Then ask:
- What are the essential proteins? (required for replication or viability — cannot be mutated away)
- Which are surface-exposed? (accessible to drugs and antibodies)
- Which are conserved across strains? (targeting conserved regions prevents resistance escape)
These three questions define your drug targets and vaccine candidates. Organisms in the same genus share targets — look up drug precedent for related pathogens before predicting from scratch.
LOOK UP DON'T GUESS: Never assume a pathogen's taxonomy, genome size, or protein function. Always call BVBRC_search_taxonomy or UniProt_search first. Even well-known pathogens have strains with different drug susceptibility profiles — look up the specific strain when known.
When to Use
Apply when user asks:
- "New pathogen detected - what drugs might work?"
- "Emerging virus [X] - therapeutic options?"
- "Drug repurposing candidates for [pathogen]"
- "What do we know about [novel coronavirus/bacteria]?"
- "Essential targets in [pathogen] for drug development"
- "Can we repurpose [drug] against [pathogen]?"
Critical Workflow Requirements
1. Report-First Approach (MANDATORY)
- Create
[PATHOGEN]_outbreak_intelligence.md FIRST with section headers
- Progressively update as data is gathered
- Output separate files:
[PATHOGEN]_drug_candidates.csv, [PATHOGEN]_target_proteins.csv
2. Citation Requirements (MANDATORY)
Every finding must have inline source attribution:
### Target: RNA-dependent RNA polymerase (RdRp)
- **UniProt**: P0DTD1 (NSP12)
- **Essentiality**: Required for replication
*Source: UniProt via `UniProt_search`, literature review*
Phase 0: Tool Verification
Known Parameter Corrections
| Tool | WRONG Parameter | CORRECT Parameter |
|---|
NCBIDatasets_get_taxonomy | name | tax_id (integer) or use BVBRC_search_taxonomy for keyword search |
UniProt_search | name | query |
ChEMBL_search_targets | query, target | pref_name__contains (substring match) |
get_diffdock_info | protein_file | protein (content) |
drugbank_full_search | (may fail) | Use drugbank_vocab_search as primary DrugBank lookup |
PubMed tip: Use sort="relevance" (default) not sort="pub_date" — date-sorted queries can return empty for narrow topics. Tool name: PubMed_search_articles.
FDA labels: Use FDA_get_drug_label_info_by_field_value with targeted return_fields to avoid oversized responses from OpenFDA_search_drug_labels.
Workflow Overview
Phase 1: Pathogen Identification
├── Taxonomic classification (NCBI Taxonomy)
├── Closest relatives (for knowledge transfer)
├── Genome/proteome availability
└── OUTPUT: Pathogen profile
|
Phase 2: Target Identification
├── Essential genes/proteins (UniProt)
├── Conservation across strains
├── Druggability assessment (ChEMBL)
└── OUTPUT: Prioritized target list (scored by essentiality/conservation/druggability/precedent)
|
Phase 3: Structure Prediction (NvidiaNIM)
├── AlphaFold2/ESMFold for targets
├── Binding site identification
├── Quality assessment (pLDDT)
└── OUTPUT: Target structures (docking-ready if pLDDT > 70)
|
Phase 4: Drug Repurposing Screen
├── Approved drugs for related pathogens (ChEMBL)
├── Broad-spectrum antivirals/antibiotics
├── Docking screen (get_diffdock_info)
└── OUTPUT: Ranked candidate drugs
|
Phase 4.5: Pathway Analysis
├── KEGG: Pathogen metabolism pathways
├── Essential metabolic targets
├── Host-pathogen interaction pathways
└── OUTPUT: Pathway-based drug targets
|
Phase 5: Literature Intelligence
├── PubMed: Published outbreak reports
├── BioRxiv/MedRxiv: Recent preprints (CRITICAL for outbreaks)
├── ArXiv: Computational/ML preprints
├── OpenAlex: Citation tracking
├── ClinicalTrials.gov: Active trials
└── OUTPUT: Evidence synthesis
|
Phase 6: Report Synthesis
├── Top drug candidates with evidence grades
├── Clinical trial opportunities
├── Recommended immediate actions
└── OUTPUT: Final report
Phase Summaries
Phase 1: Pathogen Identification
Classify via NCBI Taxonomy (query param). Identify related pathogens with existing drugs for knowledge transfer. Determine genome/proteome availability.
Genome assembly availability and QC: After classifying the pathogen, use NCBIDatasets_list_genomes_by_taxon (params taxon as tax_id, limit, reference_only) to find the reference genome, NCBIDatasets_get_genome_assembly (param accession, e.g. "GCF_000005845.2") for assembly metrics (length, N50, GC%, contig/chromosome counts), and NCBIDatasets_get_sequence_reports (param accession) to map replicons (chromosomes/plasmids with RefSeq/GenBank accessions). For the full assembly-QC-to-characterization workflow, see the tooluniverse-microbial-genome-characterization skill.
Open pathogen genomic surveillance: For the priority pathogens covered by Pathoplexus (west-nile, ebola-zaire, ebola-sudan, cchf, mpox), use Pathoplexus_count_sequences (params organism, group_by e.g. geoLocCountry or lineage) to gauge sequencing volume and geographic/lineage spread, and Pathoplexus_get_mutations (params organism, min_proportion e.g. 0.95) to pull characteristic high-prevalence mutations for the circulating population. Use early to quantify outbreak footprint and flag conserved mutations before target selection.
Knowledge transfer principle: Drugs effective against related pathogens are the highest-priority repurposing candidates. A protease inhibitor for SARS-CoV-1 is immediately relevant to SARS-CoV-2. Look up the related pathogen's approved drugs in ChEMBL before generating candidates from first principles.
Phase 2: Target Identification
Search UniProt for pathogen proteins (reviewed). Check ChEMBL for drug precedent. Score targets by: Essentiality (30%), Conservation (25%), Druggability (25%), Drug precedent (20%). Aim for 5+ targets.
Phase 3: Structure Prediction
Use NvidiaNIM AlphaFold2 for top 3 targets. Assess pLDDT confidence. Only dock structures with pLDDT > 70 (active site > 90 preferred). Fallback: alphafold_get_prediction or ESMFold_predict_structure.
Phase 4: Drug Repurposing Screen
Source candidates from: related pathogen drugs, broad-spectrum antivirals, target class drugs (DGIdb). Dock top 20+ candidates via get_diffdock_info. Rank by docking score and evidence tier.
Phase 4.5: Pathway Analysis
Use KEGG to identify essential metabolic pathways. Map host-pathogen interaction points. Identify pathway-based drug targets beyond direct protein inhibition.
Phase 5: Literature Intelligence
Search PubMed (peer-reviewed), BioRxiv/MedRxiv (preprints - critical for outbreaks), ArXiv (computational), ClinicalTrials.gov (active trials). Track citations via OpenAlex. Note: preprints are NOT peer-reviewed.
Phase 6: Report Synthesis
Aggregate all findings into final report. Grade every candidate. Provide 3+ immediate actions, clinical trial opportunities, and research priorities.
Evidence Grading
| Tier | Symbol | Criteria | Example |
|---|
| T1 | [T1] | FDA approved for this pathogen | Remdesivir for COVID |
| T2 | [T2] | Clinical trial evidence OR approved for related pathogen | Favipiravir |
| T3 | [T3] | In vitro activity OR strong docking + mechanism | Sofosbuvir |
| T4 | [T4] | Computational prediction only | Novel docking hits |
Completeness Checklist
Phase 1: Pathogen ID
Phase 2: Targets
Phase 3: Structures
Phase 4: Drug Screen
Phase 5: Literature
Phase 6: Recommendations
Fallback Chains
| Primary Tool | Fallback 1 | Fallback 2 |
|---|
NvidiaNIM_alphafold2 (requires NVIDIA_API_KEY env var; free key at build.nvidia.com) | alphafold_get_prediction (AlphaFold DB by UniProt) | ESMFold_predict_structure |
get_diffdock_info | NvidiaNIM_boltz2 (requires NVIDIA_API_KEY env var; free key at build.nvidia.com) | Manual docking |
NCBIDatasets_suggest_taxonomy | UniProtTaxonomy_get_taxon | Manual classification |
ChEMBL_search_drugs | drugbank_vocab_search | PubChem bioassays |
References
